GSK3A and colorectal carcinoma: Interestingly, asparaginase has been shown to be effective in treating CRC with mutations that inhibit GSK3α – such as those caused by R-spondin fusions – but was ineffective in APC and β-catenin mutant CRCs, which represent the vast majority of cases.